Aveanna Healthcare Holdings Inc. shares surged to an all-time high of $13.44 on Tuesday, extending a 79% gain over the past year as the home healthcare provider reported revenue that exceeded expectations.
The company’s market capitalization rose to $2.92 billion, according to market data. Aveanna’s second-quarter 2026 revenue totaled $670.5 million, a 13.7% increase from the same period last year and above the $638.62 million forecasted by analysts. The stock’s 52-week high stood at $13.39, underscoring the recent upward momentum.
Analysts at Raymond James raised their price target on Aveanna to $15 from $13 while maintaining a Strong Buy rating. Six analysts have revised their earnings estimates upward for the upcoming period, according to InvestingPro. The firm’s ProPicks AI model also flagged the upward revisions as a positive signal.
The company’s recent rally coincides with a secondary offering of 15 million shares of common stock. Affiliates of J.H. Whitney Equity Partners VII, LLC, along with certain current and former directors and officers of Aveanna, participated in the offering. Underwriters retained a 30-day option to purchase up to an additional 2.25 million shares from the J.H. Whitney affiliates.
Aveanna Healthcare, which operates in the home healthcare sector, has seen its shares climb steadily amid broader investor optimism toward healthcare services providers. The company’s financial performance and analyst upgrades have contributed to the recent surge in trading activity.
